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Abstract
Besides traditional risk factor, it has been proved that genetics and gene–environment 
interaction have a possible independent role in the development and progression of 
peripheral arterial disease (PAD). Knowledge about such genetic factors will increases 
our understanding about pathophysiologic mechanisms of PAD and could facilitate the 
therapeutic approaches. Human genetics has gone through an advanced improvement 
and it increases our chance to acquire better diagnostic and therapeutic approaches. In 
this chapter, we try to provide an update on the genetics of PAD, which is mostly about 
genome-wide association studies, linkage analyses, heritability, candidate gene studies, 
and epigenetics. Finally, we discuss challenges and future developments of researches in 
PAD genetics.
Keywords: peripheral arterial disease, genetics, genome-wide association study, linkage 
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1. Introduction
Common cause of PAD is atherosclerosis. Besides environmental risk factors (e.g., smoking, 
gender, age), some heritable risk factors are described for atherosclerosis. These are included 
hyperlipidemia, hypertension and diabetes mellitus. A reliable genetic marker could identify 
those individuals with PAD and accelerate their treatment. Besides, finding new genetic tar-
gets uncover new insights to the pathophysiology of PAD, and consequently new target for 
the cure. Earlier studies suggested heritability of PAD [1–4]. One study on monozygotic and 
dizygotic pairs revealed that with the similar environmental risk factors 48% variability of 
Ankle brachial Index (ABI) could be explained by additive genetic effects [2]. GENOA study 
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(Genetic Epidemiology Network of Arteriopathy) and the Framingham Offspring cohort 
study also found heritability in ABI variations [3, 4]. The degree of genetic variations on the 
PAD, regardless of the influences of other risk factors, remains to be revealed.
2. Genetic studies
Table 1 demonstrates comparisons between different genetic tests.
2.1. Linkage analysis
Genetic linkage analysis has the power to identify parts of genome that contain genes that 
could be inherited together. In this kind of genetic study, low resolution genome scanning 
investigates for genetic markers (microsatellites and Single nucleotide polymorphisms-SNPs) 
and that are pass to the next generation with the phenotype of interest. The results express 
in logarithm of the odds (LOD). Positive LOD indicates that co-segregation of two genetic 
markers is more likely, and negative LOD favors that likelihood less likely. It is advisable to 
consider LOD more than three statistically significant [5]. Next step is then to map neighbor-
ing region of the genome with tied association between genetic marker and phenotype.
Three studies demonstrated relation between different loci and PAD [3, 6]. First Gudmundsson 
and colleagues [6], identified a locus as “PAOD1” on chromosome 1p31 (LOD = 3.93; 
p = 1.04 × 10−5) conferring susceptibility to PAD even after nullifying the effects of diabetes 
mellitus, hypertension and hyperlipidemia. Interestingly, the genes responsible for PAOD1 
did not identified which is not surprising based on the difficulties for analyzing genetic back-
ground of a complex disease such as PAD. Another study demonstrated the association of 
ankle-brachial index (ABI) with 250 microsatellite markers on chromosomes 1p, 6q, 7q, and 
10p in 1310 African Americans and on chromosomes 3p and 3q in 796 non-Hispanic whites [3]. 
This study was also unable to demonstrate any evidence of linkage to the PAD trait.
Genetic test type Advantages Disadvantages
Single gene/panel gene 
sequencing
Cost; no off-target incidental findings Low sensitivity
Oligonucleotide 
microarray
High resolution, good copy number 
detection
No detection of balanced rearrangements
Genome sequencing Full coverage of DNA sequence Cost, turnaround time, analytical challenges, 
inaccurate for SNPs with lower frequency
GWAS novel marker finding high participants number
Linkage studying different areas across the 
genome, analyzing multiple genetic 
markers at the same time
It needs a high participants number with several 
affected generations, less helpful for complex 
disorders
Table 1. Comparison of different genetic tests for PAD genetics analysis.
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Although, linkage analysis does not require specific candidate gene and scans full genome, 
it did not show promising results. That could be related to lack of large family pedigrees and 
polygenic nature of PAD. Linkage analysis cannot identify the genetic contributions arise 
from many genes each with small effect sizes.
2.2. Genome-wide association study
In this observational study, a genome-wide set of genetic variants (SNPs) can be screened 
in a large cohorts of patients. This approach determines the associations between SNPs and 
specific phenotype compared to control individuals. Unlike linkage analysis, GWAS has the 
ability to detect modest genotypic effects.
In one study rs10757278 SNP at 9p21 was found to be associated with PAD (OR = 1.14, 
p = 6.1 × 10−5), but exclusion of known CAD cases from sample sets reduced the effect of 
this variant significantly (OR = 1.09, p = 0.075) [7]. Another similar study showed an 
association between 9p21 SNP (rs 1,333,049) with severity and prevalence of PAD [8]. 
A Japanese study on 785 PAD and 20,134 control individuals found rs9584669 in IPO5/
RAP2A related protein 2A (OR = 0.58, p = 6.78 × 10−14), rs6842241 in endothelin receptor 
type A (ENDRA gene; p = 5.32 × 10−9), and rs2074633 in histone deacylase 9 (HDAC9 gene; 
p = 8.43 × 10−8) loci with susceptibility to PAD [9]. Thorgeirsson et al. identified a com-
mon variant (rs1051730) in the nicotinic acetylcholine receptor gene cluster on chro-
mosome 15q24 with higher risk for PAD (OR = 1.19, P = 1.4 × 10−7) [10]. A GWAS 
study found rs7025486 at 9q33 associated with PAD (OR = 1.14, p = 3.9 × 10−5) [11]. 
An investigation performed on 699 PAD and 1540 Japanese controls identified 
rs1902341-A to have a strong association with PAD (OR = 1.31, p = 4.7 × 10−7) [12]. 
A recent meta-analysis with a total of 41,692 participants of European ancestry demonstrated 
that rs10757269 at 9p21 had the strongest association with ABI and achieved genome-wide 
significance (p = 2.46 × 10−8) [13].
After above mentioned meta-analysis, one study investigated 537,872 SNPs in 1641 PAD 
and 1604 control individuals in The Electronic Medical Records and Genomics consortium 
(eMERGE)-based GWAS of PAD [14]. They revealed that rs653178 in the ATXN2-SH2B3 locus 
was significantly associated with PAD (OR = 1.22, p = 6.46 × 10−7). Another outcome of this 
study was that neither loci was linked to PAD after investigation of prior known SNPs related 
to PAD. eMERGE analyses of PAD GEWAS results could not reveal any strong associations 
between SNPs and PAD by investigating of mitochondrial SNPs and haplogroups in 1652 
PAD and 1629 control individuals [15].
2.3. Candidate gene studies
This kind of study focuses on differences in allele frequency of a known specific variant 
between cases and controls among unrelated individuals. With ability for finer mapping of 
the causal variant, association studies demonstrate greater power to detect modest genetic 
effects. Generally, search of insertions, deletions, and individual SNPs among cases and con-
trols points out to genes to be associated with the development of atherosclerosis and changes 
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in various vascular biology pathways such as lipid metabolism [16], hemostasis [17–21], 
homocysteine [22–24], inflammation [25, 26], angiotensin converting enzyme [27], leukocyte 
adhesion [28], platelet activation and aggregation [29, 30], endothelial function [31, 32], and 
smooth muscle cell migration. A recent meta-analysis of around 50,000 SNPs and across 
about 2100 genes found only three SNPs associated with ABI or PAD [33]. They demonstrated 
that rs2171209 in SYTL3 (p = 6.02 × 10−7) (originally linked to lipoprotein (a)) and rs290481 in 
TCF7L2 (p = 7.01 × 10−7) (linked to diabetes mellitus type 2) were significantly associated with 
ABI and CYP2B6 (p = 4.99 × 10−5) (linked to smoking behavior) was associated to PAD.
2.4. Epigenetics
By definition, epigenetics is a science of long-lived or even hereditary modification of 
gene function without alteration of DNA sequence. In epigenetics, DNA could go through 
methylation, histone post-translational modifications, or microRNAs (miRNA), long non-
coding RNA (lncRNA) mechanisms [34, 35]. miRNAs are small (≈22 nucleotides) single-
stranded RNAs that inhibit translation of mRNA after binding to a target gene. Each 
miRNA can regulate several genes, because they do not require 100% base pair match. 
lncRNAs defined as more than 200 nucleotide long transcripts with function other than 
translation to protein.
Epigenetic changes have been described in association with some PAD risk factors [36, 37]. 
Hyperhomocysteinemia induces DNA methylation and could contribute to develop-
ment and progression of PAD [36]. DNA hypomethylation caused by smoking has been 
reported [37].
Most of the epigenetic studies relevant to PAD are currently about miRNAs. There are two 
approaches to explore the role of miRNA in PAD. They have involved either a small num-
ber of candidate intracellular miRNA which are known for their role in vascular diseases or 
the measure of a large cluster of miRNAs by microarrays. A miRNA SYBR Green Real-Time 
PCR assessed the alteration of miR-130a, miR-27b and miR-210 expression in PAD [38]. A 
whole-genome miRNA transcriptome profiling revealed downregulation of 12 miRNAs in 
PAD compared to controls [39]. Later, the same research group detected significant down-
regulation of miR-15a, miR-196b, and let-7e and upregulation of miR-411 in 40 PAD and 40 
control individuals [40].
Alterations in mitochondrial DNA (mtDNA) were proposed as a pathway for myopathy in 
PAD [41]. Mitochondrial dysfunction could be as a result of bouts of ischemia in these patients 
which causes damage to mitochondrion (mitochodriopathy).
2.5. Whole genome/exome sequencing
While massively parallel sequencing has not been performed on PAD patients specifically, 
some results from researches on atherosclerosis could be attributed to PAD. In one study, 
exonic regions of two persons with the early atherosclerosis were sequenced with next gen-
eration sequencing platform, and they revealed a rare missense mutation (Ser818Cys) in 
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INO80D, a subunit of the human INO80 chromatin remodeling complex [42]. INO80 complex 
is involved in cardiovascular physiology and development [43]. Another study repeated this 
result in two patients with aortic hypoplasia, diffuse atherosclerosis, and PAD.
2.6. Mendelian randomization
This epidemiologic study design incorporates genetic results into epidemiologic methods. 
Mendelian randomization studies offer evidence for causal relations between risk factors and 
disease outcome.
Mendelian randomization has been used to examine the relations between polymorphisms 
of specific genes and the prevalence of coronary heart disease or myocardial infarction [44]. 
Recently, it is demonstrated that each standard deviation (SD, 2.76 points) increase in body 
mass index (BMI)-composite genetic risk score was associated with 0.43 in BMI and an odds 
ratio for PAD of 1.17 [45].
3. Discussion
As multiple atherogenic pathways are involved in the pathophysiology of PAD, a profound 
monogenic effect is unlikely [46]. Environmental influences such as age, smoking, sport, eth-
nicity, and diabetes mellitus status besides genetic effects could vary the outcome for this 
disease. GWAS results are not comprehensive. It could be due to modest effect of suscep-
tible variants. To power GWAS analysis, large sample sizes are needed. GWAS results so far 
revealed limited results. Two linkage studies did not demonstrate breakthrough to identify 
significant mechanisms behind inheritance of PAD. SNPs association studies have provided 
weak and/or conflicting findings results. Next generation sequencing and epigenetics seem to 
provide some promising future. Whole-genome or exome sequencing or NGS-based RNA-
sequencing has identified new causative links between new genes and PAD. It is impera-
tive to merge deep sequencing data of the DNA findings with epigenetic data to find more 
interesting results. This is challenging as these methods produce huge amount of data to 
analyze. Environmental-Wide Association Study demonstrates gene-by-environment inter-
actions. This new method to study inter-relation between environment and genomics was a 
topic in ascertaining causality in type II diabetes mellitus [47]. They showed that the pesticide 
heptachlor epoxide was associated with type II diabetes mellitus. This new method has some 
places in gene-environment studies in PAD.
In the future, we may apply personalized medicine on the basis of genetic analysis and treat 
the patient by specific therapeutic agents.
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